Tests JMT108 in adults with advanced solid tumors
Tests JMT108, an antibody drug, in adults with advanced solid tumors.
Key facts
- Who runs it
- Conjupro Biotherapeutics, Inc.
- Where
- Dallas, Fairfax, and Huntersville, United StatesSee the 3 sites
- Trial code
- Registry title
- A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 270 people, planned
- Started
- 2 Dec 2025
- Expected to end
- Sept 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- JMT108
- Record updated
- 21 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumors that have spread or cannot be removed, who have no standard treatment left or cannot tolerate it.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Locally advanced or metastatic solid tumors, confirmed by tissue or cell tests, with at least one tumor that can be measured by RECIST v1.1
- Earlier treatment
- Standard treatments did not work, were not tolerated, or none exist. Other anti-tumor treatments must have stopped at least 4 weeks before the first dose, with shorter gaps for some drugs.
Main reasons for not taking part
- Active cancer spread to the brain or the membranes around the brain and spinal cord
- Side effects from earlier treatment that have not improved to Grade 1 or less, or to baseline
- Unapproved investigational drugs within 4 weeks before the first dose
- Chemotherapy, radiotherapy, immunotherapy or other anti-tumor therapy within 4 weeks before the first dose, with some exceptions
The registry criteria, word for word
Show all 10 criteriaShow less
Other criteria
- Major Inclusion Criteria:
- Age ≥18 years
- Participants with histologically or cytologically confirmed locally advanced or metastatic solid tumors who are unresponsive or intolerant to all standard of care or have no standard of care available
- At least one evaluable tumor lesion according to RECIST v1.1
- ECOG performance status score ≤2
- Expected survival ≥ 3 months; Major Exclusion Criteria:
- Active central nervous system metastases and/or leptomeningeal metastases
- AEs from prior therapy which have not recovered to Grade ≤1 or baseline as per NCI CTCAE v5.0; Prior therapy
- Any other unapproved investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug (C1D1)
- Chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, or other anti-tumor therapies within 4 weeks prior to the first dose of the investigational drug, except in the following situations:; Nitrosoureas or mitomycin C within 6 weeks prior to the first dose of the investigational drug; Use of oral fluoropyrimidines and small-molecule targeted drugs within 2 weeks or 5 half-lives of the drug (whichever is longer) prior to the first dose of the investigational drug; Use of herbal medicine/products with anti-tumor indications within 2 weeks prior to the first dose of the investigational drug
Where in United States
- NEXT DallasDallas, United StatesContact: Shiraj Sen, MD (principal investigator)Taking people
- NEXT VirginiaFairfax, United StatesContact: Alex Spira, MD, PhD (principal investigator)Taking people
- Carolina Biooncology InstituteHuntersville, United StatesContact: Neel Gandhi, MDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors.
Read full original descriptionShow less
The main questions it aims to answer are:
* To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a) * To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b) * To evaluate how quickly JMT108 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To explore the pharmacodynamic (PD) characteristics of JMT108 * To explore the correlation between biomarker levels and preliminary efficacy
Participants will:
* Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive JMT108 by intravenous injection every 2 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years
The 3 groups in the trial
- Phase 1a Dose EscalationTreatment being tested
In the dose escalation phase, dose escalation will be conducted using a BOIN design. A total of 4 dose levels-0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, and 2 mg/kg-will be sequentially escalated.
Treatment: JMT108
- Phase 1a Dose ExpansionTreatment being tested
During the dose escalation process, dose expansion and/or exploration of different dosing frequencies (e.g., Q3W) will be conducted for the dose level that the SMC evaluates as safe/ tolerable and where anti-tumor activity is also observed.
Treatment: JMT108
- Phase 1b Cohort ExpansionTreatment being tested
Participants may be enrolled in the cohort expansion study with tumor types including but not limited to Cohort 1: lung cancer, Cohort 2: colorectal cancer, Cohort 3: hepatic cancer, Cohort 4: gastric cancer, Cohort 5: melanoma and Cohort 6: other malignant tumors (including cervical cancer, renal cancer, bile duct cancer, squamous cell head and neck cell cancer, etc.). Based on the results of Phase 1a, the SMC will discuss and determine the administration dose and frequency for the cohort expansion study. If necessary, several different doses/frequencies may be selected for cohort expansion.
Treatment: JMT108
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors
- Plain-language title
- Tests JMT108 in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 January 2026